Skip to search formSkip to main contentSkip to account menu

New Agents

Research into new physical or chemical means to treat disease.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Impact of new agents (NAs) on survival of metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-Institution retrospective analysis.
323Background: Until few years ago, docetaxel (DOC) was the only agent able to significantly prolong overall survival (OS) of… 
2017
2017
Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter…
5030Background: Abiraterone acetate (AA), cabazitaxel (CABA), and enzalutamide (ENZ) may prolong survival in mCRPC pts… 
Review
2015
Review
2015
Multidisciplinary Management of Locally Advanced Rectal Cancer--An Evolving Landscape?
2015
2015
Sequential use of new agents (NAs) after docetaxel (DOC) first line in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A pooled-analysis of the published studies.
258 Background: NAs have recently demonstrated a survival advantage in mCRPC pts progressing after DOC: two hormonal NAs (HNA… 
2015
2015
Activity of new agents (NAs) as third-line treatment in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) showing a primary resistance (PRes) to NAs-based second line therapy…
216 Background: The androgen receptor machinery remains the ultimate target of NAs in mCRPC post-DOC, abiraterone acetate (AA… 
Review
2015
Review
2015
Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter…
e16017 Background: After DOC became the reference first line treatment for mCRPC pts, cabazitaxel (CABA), abiraterone acetate (AA… 
2014
2014
Impacts of new agents for multiple myeloma on development of secondary myelodysplastic syndrome and acute myeloid leukemia.
The use of new agents (NAs) such as bortezomib, thalidomide, and lenalidomide has extended the survival of patients with multiple… 
2013
2013
Pharmacists' Roles in the Management of Hyponatremia in Patients with Heart Failure
Hyponatremia is one of the most important problems that potentially present in managing patients with heart failure (HF). It is… 
1984
1984
Placebo-controlled clinical trials in gastroenterology. A position paper of the American College of Gastroenterology.
Treatment programs for digestive diseases should be evaluated by randomized clinical trials. Under most circumstances, the best… 
1981
1981
Perspectives for adjuvant therapy.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)